HDL Structure and Metabolism During Inflammation

炎症过程中 HDL 的结构和代谢

基本信息

  • 批准号:
    7219726
  • 负责人:
  • 金额:
    $ 32.69万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-12-01 至 2011-11-30
  • 项目状态:
    已结题

项目摘要

Intimate associations exist between atherosclerosis and inflammation. The atherosclerotic process itself has features of chronic inflammation. Furthermore, the process of atherosclerosis is profoundly accelerated by chronic inflammatory disease states such as rheumatoid arthritis. Recently higher rates of first and subsequent myocardial infarctions, as well as strokes, were observed in patients with acute urinary and respiratory infections. Perhaps most notable amongst the plethora of metabolic changes that affect lipid and lipoproteins during inflammation are the structural and metabolic alterations of HDL. In practically all species there is a significant decrease of HDL cholesterol and apolipoprotein A-l (apoA-l). Serum amyloid A protein (SAA) is dramatically induced by cytokines and can even become the major apolipoprotein of HDL. The same cytokines concomitantly induce the inflammatory phospholipases particularly group MA secretory phospholipase A2 (group IIA sPLA2) that hydrolyze HDL surface phospholipids with significant metabolic sequelae. In the short term these changes are likely required for survival, but if chronically maintained could have long-term pathological consequences. The thesis of this proposal is that the acute phase phospholipases (group IIA sPLA2) act in concert with cholesterol ester transfer protein (CETP) to propel the apolipoproteins (SAA and apoA-l) associated with spherical HDL to distinct lipid-poor SAA or apoA-l entities (including prep HDL) and/or even "free" apolipoproteins. This process hold major implications for HDL function and metabolism during inflammation. Specifically, the lipid-poor apoA-l and SAA entities likely promote cholesterol efflux whilst at the same time being susceptible to accelerated catabolism.
动脉粥样硬化和炎症之间存在密切联系。动脉粥样硬化过程本身

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

FREDERICK C. DE BEER其他文献

FREDERICK C. DE BEER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('FREDERICK C. DE BEER', 18)}}的其他基金

Serum Amyloid A, Inflammasome Activation, and Abdominal Aortic Aneurysms
血清淀粉样蛋白 A、炎症小体激活和腹主动脉瘤
  • 批准号:
    9213910
  • 财政年份:
    2017
  • 资助金额:
    $ 32.69万
  • 项目类别:
Analytical and Preparative Core
分析和准备核心
  • 批准号:
    7219730
  • 财政年份:
    2006
  • 资助金额:
    $ 32.69万
  • 项目类别:
SR-BI MEDIATED SELECTIVE CHOLESTEROL ESTER UPTAKE
SR-BI 介导的选择性胆固醇酯摄取
  • 批准号:
    6509679
  • 财政年份:
    2001
  • 资助金额:
    $ 32.69万
  • 项目类别:
SAA and sPLA2 Role in Atherogenesis
SAA 和 sPLA2 在动脉粥样硬化形成中的作用
  • 批准号:
    6618079
  • 财政年份:
    2001
  • 资助金额:
    $ 32.69万
  • 项目类别:
SR-BI MEDIATED SELECTIVE CHOLESTEROL ESTER UPTAKE
SR-BI 介导的选择性胆固醇酯摄取
  • 批准号:
    6866412
  • 财政年份:
    2001
  • 资助金额:
    $ 32.69万
  • 项目类别:
SAA and sPLA2 Role in Atherogenesis
SAA 和 sPLA2 在动脉粥样硬化形成中的作用
  • 批准号:
    6442685
  • 财政年份:
    2001
  • 资助金额:
    $ 32.69万
  • 项目类别:
SR-BI MEDIATED SELECTIVE CHOLESTEROL ESTER UPTAKE
SR-BI 介导的选择性胆固醇酯摄取
  • 批准号:
    6707547
  • 财政年份:
    2001
  • 资助金额:
    $ 32.69万
  • 项目类别:
SAA and sPLA2 Role in Atherogenesis
SAA 和 sPLA2 在动脉粥样硬化形成中的作用
  • 批准号:
    6779922
  • 财政年份:
    2001
  • 资助金额:
    $ 32.69万
  • 项目类别:
SR-BI MEDIATED SELECTIVE CHOLESTEROL ESTER UPTAKE
SR-BI 介导的选择性胆固醇酯摄取
  • 批准号:
    6629853
  • 财政年份:
    2001
  • 资助金额:
    $ 32.69万
  • 项目类别:
SR-BI MEDIATED SELECTIVE CHOLESTEROL ESTER UPTAKE
SR-BI 介导的选择性胆固醇酯摄取
  • 批准号:
    6286827
  • 财政年份:
    2001
  • 资助金额:
    $ 32.69万
  • 项目类别:

相似海外基金

Clinical application of boron-conjugated adenovirus vector for neutron capture therapy
硼缀合腺病毒载体中子捕获治疗的临床应用
  • 批准号:
    19K09482
  • 财政年份:
    2019
  • 资助金额:
    $ 32.69万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Vascular-targeted gene therapy to block proliferation of smooth muscle cells using a novel adenovirus vector
使用新型腺病毒载体进行血管靶向基因治疗以阻止平滑肌细胞增殖
  • 批准号:
    2273599
  • 财政年份:
    2019
  • 资助金额:
    $ 32.69万
  • 项目类别:
    Studentship
Gene therapy for diabetes mellitus based on the suppression of lipotoxicity using an improved adenovirus vector
使用改进的腺病毒载体抑制脂毒性的糖尿病基因治疗
  • 批准号:
    18K14964
  • 财政年份:
    2018
  • 资助金额:
    $ 32.69万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanisms of induction of mucosal immunity by adenovirus vector vaccine
腺病毒载体疫苗诱导粘膜免疫的机制
  • 批准号:
    16K18873
  • 财政年份:
    2016
  • 资助金额:
    $ 32.69万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Hemophilia B Gene Therapy via CRISPR/Cas9-Targeted Integration of the Factor IX Gene using Adenovirus Vector Delivery
使用腺病毒载体递送通过 CRISPR/Cas9 靶向整合因子 IX 基因进行 B 型血友病基因治疗
  • 批准号:
    9193681
  • 财政年份:
    2016
  • 资助金额:
    $ 32.69万
  • 项目类别:
Gene therapy for diabetes mellitus and gene function analysis using a novel adenovirus vector
使用新型腺病毒载体进行糖尿病基因治疗和基因功能分析
  • 批准号:
    15K18939
  • 财政年份:
    2015
  • 资助金额:
    $ 32.69万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Innate immue response through glycolipids by adenovirus-vector
腺病毒载体通过糖脂产生先天免疫反应
  • 批准号:
    26450450
  • 财政年份:
    2014
  • 资助金额:
    $ 32.69万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of a novel method for highly efficient gene targeting by adenovirus vector on human naive pluripotent stem cells
开发一种通过腺病毒载体高效基因靶向人类幼稚多能干细胞的新方法
  • 批准号:
    26893253
  • 财政年份:
    2014
  • 资助金额:
    $ 32.69万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Development of targeting adenovirus vector as boron carrier for boron neutron capture therapy
开发靶向腺病毒载体作为硼中子捕获疗法的硼载体
  • 批准号:
    26462183
  • 财政年份:
    2014
  • 资助金额:
    $ 32.69万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of adenovirus vector lacking VA RNA genes for efficient microRNA expression
开发缺乏 VA RNA 基因的腺病毒载体以实现有效的 microRNA 表达
  • 批准号:
    24701021
  • 财政年份:
    2012
  • 资助金额:
    $ 32.69万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了